Merck has launched construction of a $1 billion biologics facility in Wilmington, set to become the U.S. production hub for ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 construction jobs expected on the job site. The laboratory component of the new site ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Merck will invest $1 billion in a Delaware plant to manufacture Keytruda, as drugmakers ramp up U.S. production ahead of ...

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

Officials with Merck Biopharmaceutical Company broke ground on a new, 470,000 square foot biologics center at the Chestnut ...

Portugal's Galp will be gradually restarting units at its Sines oil refinery over the coming days after the major Iberian ...

U.S. President Donald Trump called Amazon Executive Chairman Jeff Bezos on Tuesday morning to complain about a report the ...